Zogenix announces positive top-line results from second pivotal phase 3 clinical trial
Zogenix reported positive top-line results from its second confirmatory Phase 3 study (Study 1504) for its investigational drug, ZX008, for treatment of children and young adults with Dravet syndrome. The study results successfully met the primary endpoint and all key secondary endpoints. July 12, 2018